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Objective
To study the in vitro and in vivo activity of LZD, VAN and
its combinations with RIF in a rabbit meningitis model,




MICs (mg/L): Strain A (LZD = 2, VAN = 1, RIF = 0.018)
and B (LZD = 4, VAN = 8, RIF = 512). The bactericidal
activity and synergy (time-kill curves) were studied over
24 h. Drugs were tested for a range of concentrations
according to their MICs and achievable human serum lev-
els (1/4x-4xMIC) against both strains.
In vivo
New Zealand rabbits (2.5–3 kg) were used, with an inoc-
ulum of 8.5–9 Log cfu/mL. PK/PD parameters (blood and
CSF) were determined (Cmax [mg/L]; AUC [mg.h/L]; t1/2
[h]; t > MIC [h]; AUC/MIC) after a single dose of each
antimicrobial on infected rabbits. In the therapy experi-
ments, animals (n = 6 per schedule) were grouped in
untreated (CON), or treated with LZD (20 mg/kg), VAN
(25 mg/kg every 4 hours, 4 doses), RIF (15 mg/kg) every
24 hours (1 dose), LZD+RIF or VAN+RIF. CSF variables
analyzed at 0, 4, 6 and 24 h of treatment were: bacterial
concentration (Log10 cfu/mL), WBC (cells/mL), lactate
(mmol/L) and protein concentration (g/L). Statistical
Analysis: Wilcoxon and Anova test were used.
Results
In vitro
The following schedules were bactericidal: Strain A: LZD
(4xMIC) and the following combinations RIF
(2xMIC)+LZD(4xMIC), RIF (1xMIC)+LZD (1/2xMIC),
RIF (1/2xMIC)+LZD (1xMIC); and strain B: VAN (4xMIC,
2xMIC) and the combinations of both drugs with RIF.
In vivo
PK/PD Cmax (μg/mL): Blood: LZD 20.84, VAN 59.59, RIF
52.38, CSF: LZD 4.64, VAN 4.12; RIF 1.22. Percentage of
penetration: LZD 19%; VAN 15%; RIF 3.8%.
Bacterial concentration (0, 4, 6, 24 h): Strain A: CON
(4.94, 4.48, 4.76, 4.65), LZD (4.96, 4.71, 4.81, 4.27),
VAN (5.25, 4.62, 4.30, 4.95), RIF (5.32, 5.65, 5.19, 4.80),
LDZ+RIF (4.85, 4.90, 4.82, 4.17) and VAN+RIF (5.34,
5.30, 5.36, 4.61); Strain B: CON (5.19, 4.67, 4.81, 4.37),
LZD (4.85, 4.37, 4.18, 3.67), VAN (5.00, 5.63, 4.79, 4.79)
and LDZ+RIF (5.02, 4.90, 4.53, 4.21). For Strain B, LZD
and LZD+RIF significantly reduced bacterial concentra-
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tion (24 h vs. 0 h, p < 0.05). LZD reduced the CSF lactate
and proteins levels (24 h vs. 0 h, p < 0.05).
Conclusion
In this model of experimental meningitis caused by a
GISA strain, linezolid and linezolid plus rifampin were
effective reducing the CSF bacterial concentration and
inflammatory parameters.Page 2 of 2
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